Anti-albuminuric effect of losartan versus amlodipine in hypertensive Japanese patients with type 2 diabetes mellitus: A prospective, open-label, randomized, comparative study  by Ohno, Yasuhiro et al.
C U R R E N T T H E R A P E U T I C R E S E A R C H
V O L U M E 68,  N U M B E R 2 ,  M A R C H / A P R I L 2007
94 Copyright © 2007 Excerpta Medica, Inc.
Anti-Albuminuric Effect of Losartan Versus
Amlodipine in Hypertensive Japanese Patients
with Type 2 Diabetes Mellitus: A Prospective,
Open-Label, Randomized, Comparative Study
Yasuhiro Ohno, MD, PhD; Akiyoshi Nishimura, MD, PhD; Hiroshi Iwai, MD, PhD;
Noriyuki Hirota, MD, PhD; Takaaki Yamauchi, MD, PhD; Mika Fujimoto, MD, PhD;
Toshiyuki Miyatake, MD, PhD; Hiroshi Arai, MD, PhD; and Norihiko Aoki, MD, PhD
Department of Endocrinology, Metabolism and Diabetes, Kinki University School of
Medicine, Osaka-Sayama, Japan
ABSTRACT
Background: The antiproteinuric effect of the angiotensin II receptor-
antagonist losartan has been observed in patients with type 2 diabetes mellitus
(T2DM). Proteinuria is considered to be a predictor of the progression of kidney
disease.
Objective: The aims of the present study were to compare and examine the
ability of losartan and amlodipine to ameliorate albuminuria in hypertensive
Japanese patients (systolic blood pressure ≥140 mm Hg or diastolic blood pres-
sure ≥90 mm Hg) with T2DM and whether the change in albuminuria was asso-
ciated with a change in glomerular filtration rate (GFR).
Methods: This prospective, open-label, randomized, comparative study was
conducted over 3 months at the Kinki University School of Medicine, Osaka-
Sayama, Japan. Hypertensive patients with T2DM were enrolled and randomly
assigned to 1 of 2 study groups receiving either losartan (25–100 mg/d) or the
calcium channel-blocker amlodipine (2.5–5 mg/d). Urinary albumin excretion
(UAE), creatinine clearance, and GFR were recorded at study initiation (base-
line) and study end (month 3). The GFR was measured from the fractional renal
accumulation of 99mTc-diethylenetriaminepentaacetic acid. Adverse events (AEs)
were monitored by a clinical research nurse during the examination.
Results: Fifty patients were asked to enroll and 38 returned the informed
written consent. Thirty-five Japanese patients were included in the final study
analysis. Seventeen patients were assigned to the losartan group (male sex, 10
[58.8%]; mean [SD] age, 58.1 [8.2] years) and 18 were assigned to the amlodi-
pine group (male sex, 10 [55.6%]; mean [SD] age, 57.4 [8.9] years); no significant
between-group difference in demographics was observed. A significant decrease
from baseline to month 3 of mean (SD) UAE was observed in the losartan group
(352.5 [556.6] mg/d vs 275.7 [466.1] mg/d; P = 0.048). No significant difference in
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mean (SD) UAE was observed in the amlodipine group for the same time period
(298.2 [416.6] mg/d vs 322.7 [415.4] mg/d). There was a statistically significant
difference found in the mean (SD) percent change of UAE from baseline to
month 3 in the losartan group compared with the amlodipine group (–23.52
[28.42] vs +27.90 [63.51]; P = 0.004). Neither group was associated with a signifi-
cant change in GFR during the course of the study. No patient discontinued the
study due to AEs that were considered, by the investigator, to be possibly or
probably associated with study treatment.
Conclusions: Treatment with losartan, but not amlodipine, was associated
with a reduction in albuminuria in these hypertensive Japanese patients with
T2DM within a period as short as 3 months. Neither drug was associated with
a significant change in GFR. Therefore, the reduction of UAE was independent
of a change in the GFR. (Curr Ther Res Clin Exp. 2007;68:94–106) Copyright ©
2007 Excerpta Medica, Inc.
Key words: albuminuria, hypertension, glomerular filtration rate, losartan,
amlodipine.
INTRODUCTION
Of the many factors involved in the pathophysiology of proteinuric kidney
diseases (eg, diabetic nephropathy), angiotensin II influences functional and
morphologic deterioration of the kidney via a renal hemodynamic effect and
nonhemodynamic cellular responses.1 In the case of patients with hyper-
tension and chronic kidney disease, hypertension plays an adverse role by
influencing the progression of kidney diseases. Once the permselectivity of
the glomerular membrane is impaired, glomerular hypertension becomes a
catalyst for excessive filtering of proteins through glomerular capillaries.2
Therefore, proteinuria is considered as a possible predictor of the progres-
sion of kidney disease. Strong arguments have also been made3–5 that pro-
teinuria is an underlying factor for the mechanisms of progression of kidney
diseases. In the case of diabetic nephropathy, there is concern that glycosy-
lated albumin might be nephrotoxic, inciting an inflammatory response lead-
ing to glomerular and interstitial damage.6 Indeed, abnormal amounts of fil-
tered protein might contribute directly to the pathogenesis of progressive
renal injury.1
The inhibitive effect on the renin-angiotensin system (RAS) by angiotensin-
converting enzyme (ACE) inhibitors and angiotensin II receptor-antagonists
(AIIAs) for the prevention of progressive kidney disease and proteinuria has
been demonstrated.7–9 However, it is not fully understood whether the antipro-
teinuric effect of RAS inhibition is associated with an improvement in the
glomerular filtration rate (GFR). A reduction in GFR might be associated with an
apparent reduction in proteinuria. However, if the antiproteinuric effect is the
consequence of a decreased GFR, the effect would not provide patients with a
total restoration of normal renal function.
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In Japan, the AIIA losartan has only been on the market since 1998. The
antiproteinuric effect of AIIA losartan has been observed in patients with type 2
diabetes mellitus (T2DM). The aims of the present study were to compare and
examine the ability of losartan and amlodipine to ameliorate albuminuria in
hypertensive Japanese patients with type 2 diabetes mellitus (T2DM), and to
compare and examine whether the change in albuminuria was associated with a
change in GFR. At the time this trial was initiated, verification of renal function
in Japanese patients had not been carried out.
PATIENTS AND METHODS
Patients and Study Design
This prospective, open-label, randomized, comparative study examined the
antialbuminuric effect of losartan, in comparison with the efficacy of the calcium
channel-blocker, amlodipine, for 3 months in patients with T2DM and hyper-
tension. Male and female outpatients of the Department of Endocrinology,
Metabolism and Diabetes, Kinki University School of Medicine, Osaka-Sayama,
Japan, aged 20 to ≤74 years were eligible for the study. Patients were enrolled if
they satisfied all of the following criteria during the 8-week screening period: 
(1) T2DM as determined by fasting plasma glucose level ≥126 mg/dL, or the result
of glucose tolerance test (75 g) at 2 hours ≥200 mg/dL, and glycosylated hemo-
globin <8.0%; (2) hypertension as determined by systolic blood pressure (SBP)
≥140 mm Hg and diastolic blood pressure (DBP) ≥90 mm Hg recorded in a sitting
position at ≥2 visits (recorded after the discontinuation of antihypertensives); and
(3) albuminuria as determined by urinary albumin excretion (UAE) of ≥30 mg/d.
The study protocol was reviewed and approved by the institutional review
board of the Kinki University School of Medicine. Written informed consent was
obtained from the patients enrolled.
All antihypertensive drugs were discontinued during the pretreatment-
screening period. An overview of the study design is shown in Figure 1. After
enrollment, patients were randomly assigned (via minimizing method) to 1 of 
2 treatment groups: 1 group was treated with losartan; the other group was
treated with amlodipine. In Japan, approved daily doses of losartan and
amlodipine are 25 to 100 mg and 2.5 to 5 mg, respectively. The group of patients
assigned to receive losartan was started on 25 mg QD. The group assigned to
receive amlodipine was started on 2.5 mg QD. In cases where the patient’s com-
pliance was judged (from the existence of the hypotensive anamnesis by hyper-
tension treatment in the past) by investigator(s) to be suitable to receive higher
doses, either 50 mg of losartan or 5 mg of amlodipine was adopted as the start-
ing dose. The target goal of SBP/DBP was <130/<85 mm Hg, and if SBP/DBP did
not reach the target within 1 month, the daily dose of losartan and amlodipine
was increased, up to 100 and 5 mg, respectively.
Exclusion criteria were as follows: DBP ≥120 mm Hg; renovascular hypertension
and/or endocrine hypertension; BP control via ACE inhibitors or AIIAs; any case
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in which other antihypertensive drugs could not be discontinued; serum creati-
nine (Scr) ≥2.5 mg/dL; renal disease(s) caused by anything other than T2DM;
and pregnancy, possibility of pregnancy, or breastfeeding.
Patients were required to return to the clinic at 2 weeks and 1, 2, and 3 months
after study initiation. BP in a sitting position was measured at all visits to the
clinic. A KZ-620 sphygmomanometer (Kenzmedico Co., Ltd., Honjo City, Japan)
was used to take BP measurements. A 24-hour urine collection was performed
on the first day of treatment to obtain baseline measurements of urine volume,
UAE level, and urinary creatinine excretion (Ucr) level. This process was
repeated at the end of the study (month 3). Urinary albumin was determined
with a turbidimetric immunoassay kit (Mitsubishi Kagaku Bio-Clinical Labora-
tories, Inc., Tokyo, Japan). Creatinine clearance (Ccr), in mL/min, was calcu-
lated by the following formula10:
Ccr = Ucr × (V/Scr) × (1.73/A)
where V was urine volume (mL/min), and A was body surface area (cm2).
The GFR was measured from the fractional renal accumulation of 
99mTc-diethylenetriaminepentaacetic acid (99mTc-DTPA), calculated from com-
puted renograms with a gamma camera, according to the method described by
Gates.11 A clinical research nurse determined each patient’s compliance via
interview. Patients were asked about the frequency of administration of the
study medication. A report of ≥95% was considered good; all patients who par-
ticipated in this study reported good compliance. Adverse events (AEs) were
monitored by a clinical research nurse at the time of examination.
Losartan
25–50 mg/d
Amlodipine
2.5–5.0 mg/d
50–100 mg/d
5 mg/d
Screening (8 weeks)
Registration
Month 3
UAE
Ccr
GFR
UAE
Ccr
GFR
Month 1 Month 2Baseline Week 2
Figure 1. Study design for treatment of Japanese patients with type 2 diabetes melli-
tus and hypertension for 3 months. The starting dose was continued for 
≥1 month, and dose escalation was allowed from the beginning of month 2
if systolic blood pressure/diastolic blood pressure did not reach target
(<130/<85 mm Hg). UAE = urinary albumin excretion; Ccr = creatinine
clearance; GFR = glomerular filtration rate.
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Statistical Analysis
All values are expressed as mean (SD). The baseline characteristics of the
losartan group and the amlodipine group were compared using an unpaired
Student t test or the Fisher exact test. The difference in SBP and DBP changes
between the 2 groups was determined by an unpaired Student t test. Intragroup
changes in UAE and GFR from baseline to 3 months were analyzed by a paired
Student t test. The relationship between GFR and Ccr was analyzed using the
Pearson correlation coefficient. A P value <0.05 was considered statistically sig-
nificant. The calculation of sample size for this trial was based on the report of
Fernández-Andrade et al.12 The sample size calculations are based on an esti-
mated efficacy of the albumin urine reduction; 40% for losartan and 10% for
amlodipine at month 3. With an α level of 0.05 and a test power of 80%, the
resulting sample size was 36 patients for both treatment groups. A risk of
patients lost to follow-up of 10% was assumed. We estimated the required num-
ber of the minimum cases at 40 samples.
RESULTS
We asked 50 patients to participate in this trial and received written informed
consent from 38 patients. We allocated 19 patients to the losartan group and
19 patients to the amlodipine group. However, 1 patient in the losartan group
discontinued the study in month 3 as the result of acute heart failure. One
patient in the amlodipine group discontinued the study at month 1 as the
result of a stroke. The chief investigator (Y.O.) decided that these 2 cases were
not associated with study drug treatments. One patient in the losartan group
was fitted with a loop diuretic because of insufficient BP control and the data
from this patient were eliminated from the end point analysis. Losartan 100
and 50 mg were administered to 11 and 6 patients, respectively. The mean dose
of losartan was 82.4 mg/d at the end of the trial. All patients in the amlodipine
group (n = 18) were receiving 5 mg from the start to the end of the trial. 
No patients who were started at 5 mg of amlodipine reached <130/<85 mm Hg
within 1 month. The table summarizes the baseline demographic and clinical
characteristics of the patients who completed the study.
The BP change in each group is illustrated in Figure 2. There was a signifi-
cant change in SBP at week 4 between the losartan group and the amlodipine
group. No other significant changes in BP were observed. Figure 3A shows
UAE at baseline and at month 3 in the losartan and amlodipine groups.
Losartan was associated with a significant decrease in mean (SD) UAE from
352.5 (556.6) mg/d at baseline to 275.7 (466.1) mg/d at month 3 (P = 0.048).
However, there was no significant difference observed in the amlodipine group
in the mean (SD) UAE values between baseline and month 3 (298.2 [416.6] mg/d
vs 322.7 [415.4] mg/d, respectively). Figure 3B shows the percent change of
UAE in the losartan group and the amlodipine group. There was a statistically
significant difference in the percent change of mean (SD) UAE from baseline to
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month 3 between the 2 groups (losartan, –23.52 [28.42] vs amlodipine, +27.90
[63.51]; P = 0.004). Change in UAE from baseline to month 3, when stratified by
patients with macroalbuminuria (>300 mg/d; n = 4) and microalbuminuria
(≤300 mg/d; n = 13), was significantly greater in those patients with microalbu-
minuria (P = 0.019) (Figure 4). The GFR determined at baseline and at month 3
in the losartan group and in the amlodipine group is shown in Figure 5. There
was no statistically significant change observed in GFR in the 2 groups. Figure 6
shows regression lines for correlation between the GFR and Ccr, determined at
baseline and at month 3. At both time points, the GFR and Ccr were signifi-
cantly correlated (baseline, r = 0.68; month 3, r = 0.66).
Adverse Events
Both treatment regimens were well tolerated. No patient discontinued the
study due to AEs that were considered by the investigator to be possibly or
probably associated with study treatment. However, 2 AEs (increased serum
potassium and leukocytosis) experienced by 2 patients in the losartan group
and 6 AEs (palpitations, unsteadiness, face flushing, increased serum potas-
Table. Baseline demographic and clinical characteristics of hypertensive Japanese
patients with type 2 diabetes mellitus (T2DM) assigned to receive either losar-
tan or amlodipine. Values are presented as mean (SD), except where otherwise
noted.
Group*
Losartan Amlodipine
Characteristic (n = 17) (n = 18)
Sex, no. (%)
Male 10 (58.8) 10 (55.6)
Female 7 (41.2) 8 (44.4)
Age, y 58.1 (8.2) 57.4 (8.9)
BMI, kg/m2 24.4 (3.9) 26.5 (4.4)
SBP, mm Hg 158.5 (9.2) 160.6 (15.7)
DBP, mm Hg 83.9 (12.0) 86.8 (10.3)
FPG, mg/dL 133.0 (31.1) 145.4 (42.6)
HbA1c,% 6.8 (0.7) 6.8 (0.8)
UAE, mg/d 352.2 (556.6) 298.2 (416.6)
GFR, mL/min 81.9 (19.0) 73.9 (18.9)
T2DM duration, y 8.1 (5.2) 10.3 (6.3)
Hypertension duration, y 6.2 (3.9) 3.8 (3.9)
BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; FPG = fasting
plasma glucose; HbA1c = glycosylated hemoglobin; UAE = urinary albumin excretion; GFR = glomeru-
lar filtration rate.
*No significant between-group differences were found.
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sium, increased albuminuria, positive albuminuria) experienced by 3 patients in
the amlodipine group were reported as mild subjective and objective symp-
toms and as mild changes observed by laboratory chemistry. Although there
was a case of acute heart failure in the losartan group, there was no sign of a
connection to the study drug. Therefore, the investigator judged that losartan
did not cause the acute heart failure. Similarly, the investigator judged that 
the cerebral infarction in the amlodipine group was not caused by the use of
amlodipine.
DISCUSSION
In our present study, treatment of patients with losartan was associated with a
significant reduction of UAE from baseline levels. A significant change in UAE
was not observed in patients treated with amlodipine. The reduction of UAE
associated with losartan achieved statistical significance in patients with
microalbuminuria. The overall reduction in UAE in patients with macroalbumin-
uria was not statistically significant, and may be related to a small number of
patients and large standard deviations.
Evidence is available with respect to the effect of inhibition of angiotensin II
for reduction of proteinuria. The Reduction of Endpoints in NIDDM with the
Angiotensin II Antagonist Losartan study13 reported the renoprotective efficacy
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Figure 2. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) in patients
of the losartan group (n = 17) and the amlodipine group (n = 18) during 
3 months of study. Values are presented as mean (SD). *P = 0.040 versus
losartan. 
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Figure 3. (A) Urinary albumin excretion (UAE) at baseline and at month 3 in the losar-
tan group and the amlodipine group. (B) Percent change from baseline to
month 3 of UAE in the losartan and amlodipine groups. All values are pre-
sented as mean (SD). *P = 0.048 versus baseline; †P = 0.004 versus amlodipine.
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Figure 4. Urinary albumin excretion (UAE) at baseline and at month 3 in the losartan
group, stratified into subgroups of macroalbuminuria (>300 mg/d; n = 4)
and microalbuminuria (<300 mg/d; n = 13). Values are presented as mean
(SD). *P = 0.019 versus baseline. 
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Figure 5. Glomerular filtration rate (GFR) at baseline and at month 3 in the losartan
(n = 17) and amlodipine (n = 18) groups. No significant changes were
observed. Values are presented as mean (SD).
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of losartan in 1513 patients with type 2 diabetes, associated with a significant
reduction in proteinuria in patients with a median urinary albumin-to-creatinine
ratio of 1237 at baseline. In the Japanese Losartan Therapy Intended for the
Global Renal Protection in Hypertensive Patients study,14 significant reduction
of urinary protein excretion associated with the use of losartan was indepen-
dent of its BP-lowering effect in 93 patients with chronic kidney disease and
hypertension. This was in contrast to the effect associated with the use of am-
lodipine, in which there was no statistically significant reduction in urinary 
protein excretion. In a prospective study15 in 117 patients with chronic nondia-
betic nephropathies, treatment with dihydropyridine calcium channel-blockers
resulted in a significantly higher level of proteinuria than the level in patients
treated with other antihypertensive drugs (P = 0.015), although the control of BP
and the severity of underlying renal disease were similar. The use of valsartan in
332 patients with type 2 diabetes was also associated with lowered BP and an
antiproteinuric effect.16 Therefore, the present study results are comparable with
previously published reports, in regard to the positive antialbuminuric effect asso-
ciated with the blockade of angiotensin II receptors.
In the losartan group and the amlodipine group, there was no statistically
significant change in GFR as measured by renogram with 99mTc-DTPA. Although
Ccr is a useful parameter to assess renal glomerular function, on the basis of
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Figure 6. Regression analysis for correlation between the glomerular filtration rate
(GFR) and creatinine clearance (Ccr) in Japanese patients (n = 35) with type
2 diabetes mellitus and hypertension treated with losartan or amlodipine.
Values and regression lines were from determinations in all patients at base-
line (r = 0.68) and at month 3 (r = 0.66).
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the widely accepted concept that it mimics the GFR, it is true also that Ccr
does not always reflect the GFR correctly. In cases of renal failure,17 the value
of Ccr has been about twice that of the GFR value determined by inulin clear-
ance. Measurement of the GFR by renogram with the radioactive compound
99mTc-DTPA has thus been introduced. Because the diagnosis of patients by the
renogram is not common in clinical practice, we measured GFR only twice, at
baseline and at month 3. Our results demonstrated that there was no change in
the GFR from baseline to month 3 in the losartan group or in the amlodipine
group. As is shown in Figure 6, because the GFR and Ccr were significantly cor-
related, Ccr appeared to reflect the GFR. This suggested that, in our present
study, although an antiproteinuric effect was associated with losartan, renal
hemodynamics and glomerular functions were not altered.
Angiotensin II constricts the efferent arterioles to a greater extent than the
afferent arterioles, resulting in an increase in glomerular capillary filtration
pressure.17 The elevated filtration pressure and increased SBP caused by
angiotensin II might lead to an increase in the GFR. The multinational, random-
ized, double-blind, placebo-controlled Irbesartan in Patients with Type 2
Diabetes and Microalbuminuria study18 examined the effect of the AIIA irbesar-
tan in 590 patients with type 2 diabetes. A significant decline in Ccr was not
observed in a 3- to 24-month period in either the irbesartan group or the
placebo group, although a significant reduction in UAE associated with irbesar-
tan was observed from 3 months. There is concern that pharmacologic interfer-
ence of the RAS reduces the GFR and the glomerular filtration fraction.19
Therefore, in treating patients with hypertension and kidney disease, the phar-
macotherapy is required to reduce BP to the target value, and concomitantly to
maintain the GFR or, hopefully, to increase the GFR if it is below the normal
level. The use of losartan might be beneficial, in terms of maintaining the GFR
with concomitant effectiveness in reducing UAE. The single-blind, randomized,
placebo-controlled study by Gansevoort et al20 reported that losartan was
associated with changes in BP and proteinuria similar to those associated with
ACE-inhibition in patients with nondiabetic kidney disease. In a randomized,
double-blind, crossover trial, Andersen et al21 also reported that, in 16 pa-
tients with type 1 diabetic nephropathy, treatments with losartan and enalapril
for 2 months were associated with significantly reduced urinary protein excre-
tion, whereas no significant change in GFR, as measured by determination of the
radioactivity of 51Cr-ethylenediaminetetraacetic acid,22,23 was observed. There-
fore, based on the results of our study, it is our opinion that the observed
reduction of UAE in patients with diabetic nephropathy and hypertension asso-
ciated with losartan appears to occur without a change in the GFR. In our study,
the onset of the antialbuminuric effect was seen at the first measurement within
3 months of study initiation. Because the reduction in UAE is one of the targets
of treatment for renoprotection, and an early effect is expected, the early onset
of the antialbuminuric effect with no substantial change in the GFR in this
period might be highly beneficial, although longer treatment remains to be
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investigated. As a result, we carried out a number of examples using the com-
parison data of albuminuria since we did not have any comparison data of
amlodipine and losartan regarding GFR. Because this trial was of a small size
and the trial period was short, the possible conclusions from this trial outcome
are limited. It will be necessary to examine a much higher number of cases in a
longer-term trial in the future.
CONCLUSIONS
Treatment with losartan, but not amlodipine, was associated with a reduction
in albuminuria in these hypertensive Japanese patients with T2DM within a
period as short as 3 months. Neither drug was associated with a significant
change in GFR. Therefore, the reduction of UAE was independent of a change in
the GFR.
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